Sihuan Pharm announced that its non-wholly-owned subsidiary, Huisheng Pharm, has completed a RMB 500 million Series A financing. This round was invested by China Life Chengda (Shanghai) Health Industry Equity Investment Centre (L.P.), GF Investment, GF In
Senlang Biotechnology announced the successful closing of RMB 200 million from Qianhai Ark Asset Management. CEC Capital Group acted as the exclusive financial advisor for Senlang Biotechnology in this transaction.
Fosun Pharmaceutical recently announced that its subsidiary, YanengBIO, along with its existing shareholders, has entered into a relevant agreement with Yaneng Bioscience under CBridge Capital. Upon completion of the transaction, YanengBIO will transition
Yunsilicon announced the acquisition of another hundred million RMB in investment. This round was led by Lightspeed China Partners, with strategic investment from MorethanMoore, a subsidiary fund under the National IC Industry Investment Fund, and partici
DataMesh, the digital twin platform provider, has recently achieved a successful completion of its B2 round financing. The funds secured in this round are predominantly designated for the development of enterprise metaverse products and the expansion into